Literature DB >> 27790421

A Study to Assess the Validity of Estimation of Serum Ostase Level in Hyperthyroid and Hypothyroid Cases.

Polina Boruah1, Arup Jyoti Baruah2, Ranendra Hajong2, Chandan Kumar Nath3, Bhupen Barman4, Happy Chutia3, Kalyan Sarma5.   

Abstract

INTRODUCTION: One of the more specific assessments of the metabolic status of bone in normal and in disease conditions is the measurement of bone specific alkaline phosphatase or ostase. The measurement of serum ostase has several advantages over the measurements of other bone parameter. Because of its relatively long half-life, in-vivo (1 to 3days), it is relatively unaffected by diurnal variation. AIM: To find the correlation of serum ostase level in hyper and hypothyroid cases and also to study the validity of routine estimation of serum ostase in hyper and hypothyroid cases so as to monitor the base level bone health on presentation.
MATERIALS AND METHODS: Serum ostase level was studied in 74 patients with disorder of thyroid function. Serum ostase level, Thyroid Stimulating Hormone (TSH), FT3, FT4 levels were estimated by chemiluminescent technique. The instrument used was Beckman- coulter Access 2. A total of 39 patients were hypothyroid, 31 were hyperthyroid and 4 patients had subclinical hyperthyroidism.
RESULTS: The serum ostase level was found to be elevated above 40 μg/L in 26 of the cases and above 16 μg/L but below 40μg/L in 5 cases of hyperthyroidism along with decrease in Bone Mineral Density (BMD). Serum ostase level was found to be directly proportional to the serum FT3 level (Normal range of serum ostase is 8-16 μg/L).
CONCLUSION: From this study, an inference can be drawn that a routine estimation of serum ostase level in hyperthyroid cases will help in proper monitoring of decrease bone turnover as indicated by increase serum ostase level. Besides, the estimation of serum ostase level in hyperthyroid cases it is found to be valid in this study, which can turn to be an important guiding parameter to the treating physician to formulate necessary protocols and guidelines for prophylaxis, treatment and to monitor the response to therapy in cases of reduced bone turnover related to hyperthyroid state.

Entities:  

Keywords:  Bone mineral density; FT3 (Free 3, 5, 3/-triiodothyronine); FT4 (Free 3,5,3/,5/ tetraiodothyronine); Hyperthyroidism; Subclinical hyperthyroidism; Thyroid Stimulating Hormone

Year:  2016        PMID: 27790421      PMCID: PMC5071921          DOI: 10.7860/JCDR/2016/19750.8441

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  31 in total

1.  Thyroid hormone treatment of cultured chondrocytes mimics in vivo stimulation of collagen X mRNA by increasing BMP 4 expression.

Authors:  Luisa Lassová; Zeling Niu; Eleanor B Golden; Arthur J Cohen; Sherrill L Adams
Journal:  J Cell Physiol       Date:  2009-06       Impact factor: 6.384

Review 2.  Biochemical markers of bone remodeling.

Authors:  M Kleerekoper
Journal:  Am J Med Sci       Date:  1996-12       Impact factor: 2.378

3.  The c-erb-A protein is a high-affinity receptor for thyroid hormone.

Authors:  J Sap; A Muñoz; K Damm; Y Goldberg; J Ghysdael; A Leutz; H Beug; B Vennström
Journal:  Nature       Date:  1986 Dec 18-31       Impact factor: 49.962

Review 4.  Subclinical hyperthyroidism: clinical features and treatment options.

Authors:  Bernadette Biondi; Emiliano Antonio Palmieri; Michele Klain; Martin Schlumberger; Sebastiano Filetti; Gaetano Lombardi
Journal:  Eur J Endocrinol       Date:  2005-01       Impact factor: 6.664

5.  Osteoporosis in patients with subclinical hypothyroidism treated with thyroid hormone.

Authors:  Pedro J Tárraga López; Carmen Frias López; Francisco Naharro de Mora; José Antonio Rodríguez Montes; Juan Solera Albero; Antonio Naharro Mañez; Arancha Galvez Casas
Journal:  Clin Cases Miner Bone Metab       Date:  2011-09

Review 6.  Molecular aspects of thyroid hormone actions.

Authors:  Sheue-Yann Cheng; Jack L Leonard; Paul J Davis
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

7.  Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial.

Authors:  Christian Meier; Müller Beat; Merih Guglielmetti; Mirjam Christ-Crain; Jean-Jacques Staub; Marius Kraenzlin
Journal:  Osteoporos Int       Date:  2004-01-16       Impact factor: 4.507

Review 8.  Biochemical markers of bone turnover. II: Diagnosis, prophylaxis, and treatment of osteoporosis.

Authors:  B J Riis
Journal:  Am J Med       Date:  1993-11-30       Impact factor: 4.965

Review 9.  Biochemical markers of bone turnover.

Authors:  P D Delmas
Journal:  J Bone Miner Res       Date:  1993-12       Impact factor: 6.741

10.  Hyperthyroid levels of TSH correlate with low bone mineral density: the HUNT 2 study.

Authors:  Anders Svare; Tom Ivar Lund Nilsen; Trine Bjøro; Siri Forsmo; Berit Schei; Arnulf Langhammer
Journal:  Eur J Endocrinol       Date:  2009-08-11       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.